FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013659094> ?p ?o ?g. }

• W2013659094 endingPage "96" @default.
• W2013659094 startingPage "75" @default.
• W2013659094 abstract "On the basis of our observation of the increased specific activities of glutamine-utilizing enzymes in purine and pyrimidine metabolism in hepatoma 3924A, and because the concentration of glutamine is ten times lower in the hepatomas than in the liver, the biochemical pharmacology of the anti-glutamine agent, acivicin, was examined. (1) Acivicin competitively inhibited the activities of amidophosphoribosyl-transferase, CTP synthetase and carbamoyl-phosphate synthetase II from extracts of liver and hepatoma 3924A. (2) In addition to the competitive inhibition exerted by acivicin, evidence was obtained that this drug also irreversibly inactivated in vitro the glutamine-utilizing enzymes. It is particularly relevant for the selectivity of acivicin that the activity of aspartate carbamoyltransferase, an enzyme present in the same complex as carbamoyl-phosphate synthetase II, was not affected by the anti-glutamine agent. (3) Acivicin in vivo brought down the activities of glutamine-utilizing enzymes in a period of 10 min to 1 hr after injection. CTP synthetase activity declined to less than 10% of that observed in the uninjected rats. The decreases were not reversible by various in vitro methods, but in vivo the activities returned to normal range in 72 hr. (4) The activity of aspartate carbamoyltransferase, which exists as a multi-enzyme complex with synthetase II, was not altered by acivicin injection. Similar results were observed in transplantable sarcoma in the rat. (5) The acivicin-induced decrease in enzymic activities could not be restored by purification of the enzymes. (6) In vitro studies indicated that addition of acivicin to liver or hepatoma extracts or purified enzymes rapidly decreased enzymic activities; the activities could not be restored. These results are consistent with an interpretation that acivicin acts either as a tight-binding inhibitor or as an inactivator through alkylation of the enzymes of glutamine utilization. (7) Acivicin in combination with actinomycin provided a synergistic kill of hepatoma cells in tissue culture and also inhibited the growth of transplantable solid hepatoma 3924A in the rat. (8) The synergistic biological results of combination chemotherapy with acivicin and actinomycin can be accounted for by the action of acivicin in inhibiting GMP and CTP synthetases, resulting in a decrease in GTP and CTP content, and by the actinomycin-caused inhibition of RNA polymerase in selectively blocking the utilization of GTP and CTP." @default.
• W2013659094 created "2016-06-24" @default.
• W2013659094 creator A5005796279 @default.
• W2013659094 creator A5006542410 @default.
• W2013659094 creator A5017548102 @default.
• W2013659094 creator A5020614443 @default.
• W2013659094 creator A5038588938 @default.
• W2013659094 creator A5040692592 @default.
• W2013659094 creator A5052912946 @default.
• W2013659094 creator A5080041014 @default.
• W2013659094 creator A5081913506 @default.
• W2013659094 creator A5083716977 @default.
• W2013659094 date "1982-01-01" @default.
• W2013659094 modified "2023-09-23" @default.
• W2013659094 title "Multi-enzyme-targeted chemotherapy by acivicin and actinomycin" @default.
• W2013659094 cites W1557266545 @default.
• W2013659094 cites W1580729290 @default.
• W2013659094 cites W1775749144 @default.
• W2013659094 cites W1966606429 @default.
• W2013659094 cites W1968902935 @default.
• W2013659094 cites W2004566935 @default.
• W2013659094 cites W2011862846 @default.
• W2013659094 cites W2040202091 @default.
• W2013659094 cites W2070278432 @default.
• W2013659094 cites W2084561821 @default.
• W2013659094 cites W2084654792 @default.
• W2013659094 cites W2094389210 @default.
• W2013659094 cites W2127093416 @default.
• W2013659094 cites W2969240875 @default.
• W2013659094 doi "https://doi.org/10.1016/0065-2571(82)90009-7" @default.
• W2013659094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6180609" @default.
• W2013659094 hasPublicationYear "1982" @default.
• W2013659094 type Work @default.
• W2013659094 sameAs 2013659094 @default.
• W2013659094 citedByCount "45" @default.
• W2013659094 countsByYear W20136590942013 @default.
• W2013659094 countsByYear W20136590942014 @default.
• W2013659094 countsByYear W20136590942017 @default.
• W2013659094 countsByYear W20136590942019 @default.
• W2013659094 countsByYear W20136590942022 @default.
• W2013659094 crossrefType "journal-article" @default.
• W2013659094 hasAuthorship W2013659094A5005796279 @default.
• W2013659094 hasAuthorship W2013659094A5006542410 @default.
• W2013659094 hasAuthorship W2013659094A5017548102 @default.
• W2013659094 hasAuthorship W2013659094A5020614443 @default.
• W2013659094 hasAuthorship W2013659094A5038588938 @default.
• W2013659094 hasAuthorship W2013659094A5040692592 @default.
• W2013659094 hasAuthorship W2013659094A5052912946 @default.
• W2013659094 hasAuthorship W2013659094A5080041014 @default.
• W2013659094 hasAuthorship W2013659094A5081913506 @default.
• W2013659094 hasAuthorship W2013659094A5083716977 @default.
• W2013659094 hasConcept C150903083 @default.
• W2013659094 hasConcept C166342909 @default.
• W2013659094 hasConcept C181199279 @default.
• W2013659094 hasConcept C185592680 @default.
• W2013659094 hasConcept C197248121 @default.
• W2013659094 hasConcept C200159599 @default.
• W2013659094 hasConcept C202751555 @default.
• W2013659094 hasConcept C207001950 @default.
• W2013659094 hasConcept C2776476023 @default.
• W2013659094 hasConcept C2779289688 @default.
• W2013659094 hasConcept C2779349466 @default.
• W2013659094 hasConcept C515207424 @default.
• W2013659094 hasConcept C55493867 @default.
• W2013659094 hasConcept C74539022 @default.
• W2013659094 hasConcept C86803240 @default.
• W2013659094 hasConcept C98274493 @default.
• W2013659094 hasConceptScore W2013659094C150903083 @default.
• W2013659094 hasConceptScore W2013659094C166342909 @default.
• W2013659094 hasConceptScore W2013659094C181199279 @default.
• W2013659094 hasConceptScore W2013659094C185592680 @default.
• W2013659094 hasConceptScore W2013659094C197248121 @default.
• W2013659094 hasConceptScore W2013659094C200159599 @default.
• W2013659094 hasConceptScore W2013659094C202751555 @default.
• W2013659094 hasConceptScore W2013659094C207001950 @default.
• W2013659094 hasConceptScore W2013659094C2776476023 @default.
• W2013659094 hasConceptScore W2013659094C2779289688 @default.
• W2013659094 hasConceptScore W2013659094C2779349466 @default.
• W2013659094 hasConceptScore W2013659094C515207424 @default.
• W2013659094 hasConceptScore W2013659094C55493867 @default.
• W2013659094 hasConceptScore W2013659094C74539022 @default.
• W2013659094 hasConceptScore W2013659094C86803240 @default.
• W2013659094 hasConceptScore W2013659094C98274493 @default.
• W2013659094 hasLocation W20136590941 @default.
• W2013659094 hasLocation W20136590942 @default.
• W2013659094 hasOpenAccess W2013659094 @default.
• W2013659094 hasPrimaryLocation W20136590941 @default.
• W2013659094 hasRelatedWork W1519597454 @default.
• W2013659094 hasRelatedWork W163755394 @default.
• W2013659094 hasRelatedWork W1874448345 @default.
• W2013659094 hasRelatedWork W1982383123 @default.
• W2013659094 hasRelatedWork W2000814203 @default.
• W2013659094 hasRelatedWork W2013659094 @default.
• W2013659094 hasRelatedWork W2043942491 @default.
• W2013659094 hasRelatedWork W204527770 @default.
• W2013659094 hasRelatedWork W2055283392 @default.
• W2013659094 hasRelatedWork W2802160528 @default.
• W2013659094 hasVolume "20" @default.

• next